PF Strategies
Partners in Advocacy, Education and Research Innovation
Serving the Pulmonary Fibrosis and Rare Disease Communities
The goal of this meeting was to initiate planning of the “Fibrosis Roadmap” for future research needs, which meeting participants aim to publish in a multidisciplinary scientific journal. This roadmap could help guide fibrosis research funding decisions by government and private agencies.
To help set priorities for future research into fibrotic diseases and their treatments, the American Thoracic Society hosted the first “Fibrosis Across Organ Systems” symposium March 8–11, 2012, in Denver. More than 60 physicians, academic experts, and patient advocates from such groups as the Hermansky Pudlak Syndrome Network, Coalition for Pulmonary Fibrosis, and Pulmonary Fibrosis Foundation discussed fibrotic diseases of the lung, liver, kidney, heart, and skin. Corporate sponsors included Boehringer Ingelheim, Genentech, InterMune, Gilead Sciences, Sanofi, Celgene, and Stromedix.
Fibrosis Across Organs Symposium
Exploring Future Directions for Research and Treatment
March 8-11, 2012
“The physicians and researchers who participated in this meeting covered a lot of ground and worked to identify the directions we should take in the area of fibrosis,” says Gregory Cosgrove, MD, chair of the Fibrosis Across Organ Systems Organizing Committee and a pulmonologist at National Jewish Health in Denver. “The real success of this meeting will be measured by its impact on research into these diseases and the lives of the patients who suffer from them, as well as the stimulation of similar meetings around the world.”